[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunotherapy-esophagus-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunotherapy-esophagus-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100478848","phase-2-induction-tislelizumab-combined-with-chemotherapy-followed-by-definitive-chemoradiotherapy-in-the-treatment-of-locally-unresectable-esophageal-squamous-cell-carcinoma-100478848",false,"NCT05515315","Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically confirmed localized ESCC that is suitable for cCRT, including: stage II-IVA (AJCC version 8) inoperable ESCC (medically unfit for surgery or refusing surgical intervention);;\n* Aged 18-70, both sexes;\n* ECOG score 0-1\n* The presence of measurable and\u002For nonmeasurable lesions that met the definition of RECIST1.1;\n* Adequate organ and bone marrow function, meeting the following definitions:\n\n  1. Blood routine (no blood transfusion, no granulocyte colony-stimulating factor \\[G-CSF\\], and no other drugs were used within 14 days before treatment);Absolute neutrophil count (ANC) ≥1.5×109\u002FL;Hemoglobin (HB) ≥9.0 g\u002FdL;Platelet count (PLT) ≥100×109\u002FL;\n  2. Blood biochemistry Creatinine clearance rate ≥60 mL\u002Fmin;Total bilirubin (TBIL) ≤ 1.5×ULN;Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤2.5×ULN;\n* Expected survival time \\> 6 months;\n* Fertile female subjects and male subjects with partners of reproductive age are required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last treatment;\n* Patients who volunteered to participate in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* A history of fistula caused by primary tumor invasion;\n* Presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites that required repeated drainage or medical intervention (within 2 weeks before randomization);\n* Known intolerance or resistance to chemotherapy specified in the trial protocol;\n* have received any other ESCC antitumor therapy (e.g., therapy targeting PD-1, PD-L1, PD-L2 or other tumor immunotherapy, radiotherapy, targeted therapy, ablation or other systemic or local antitumor therapy);\n* Patients with active autoimmune disease or a history of autoimmune disease that may relapse, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* History of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis and acute lung disease;\n* Severe chronic or active infection (including tuberculosis infection) requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment;\n* Known history of HIV infection;\n* Other malignancies (except cured basal cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix) in the past 5 years;\n* Received live vaccine within 28 days before enrollment;\n* while participating in another therapeutic clinical trial.","ALL","18 Years","70 Years",{"count":19,"type":20},93,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)",[26],"Immunotherapy Esophagus Cancer","RECRUITING","2024-02-04",{"date":30,"type":31},"2024-02-07","ACTUAL",{"date":33,"type":31},"2022-05-31",{"date":35,"type":20},"2027-05-31",{"name":37,"class":38},"Fuzhou General Hospital","OTHER"]